Your Gateway to China

Why Hong Kong Lucrative Pharmaceutical Market with Strategic Regional Access Attractive Market Fundamentals

Hong Kong's pharmaceutical market, valued at $2.5 billion, offers a lucrative opportunity for imported drugs, propelled by:

Hong Kong is renowned for its simple and low tax system offering significant business advantages:

The regulatory framework ensures comprehensive oversight of pharmaceutical products:

However, the regulatory environment presents complexities with multiple ordinances requiring expert navigation:

The regulatory authorities strive to uphold international standards despite these complexities. Successfully navigating these regulatory complexities is crucial for tapping into the potential of Hong Kong's pharmaceutical industry, ensuring accessibility without compromising quality and safety.

Do not let regulatory complexity delay your Hong Kong market entry. Our Hong Kong-based regulatory experts, with deep knowledge of multiple ordinances and proven track record, are ready to accelerate your pharmaceutical registration in this sophisticated $2.5 billion market with 6.5% growth potential.

to discuss how our Hong Kong expertise can unlock opportunities in this strategic gateway to China markets.

We have successfully secured drug licenses across a wide range of product types, including New Chemical Entities (NCE), generics, biologics/biosimilars, radiopharmaceuticals, drug-medical device combination products, supplements, medical device licenses, and cosmetics licenses. Our extensive experience includes handling diverse product categories such as New Drug Applications (NDA), vaccines, biologics, biosimilars, radiopharmaceuticals, generics, cosmetics, health supplements, and medical devices, ensuring compliance and efficient market entry for all product types.

Marketing Authorization Holder (MAH) Representation as Regulatory and Local Responsible Person in Pharmacovigilance, liaising with the Hong Kong Department of Health (DH), efficiently handling queries and regulatory communications for MAH approval.

Handled Marketing Authorization Transfers, providing regulatory support for inventory transfer and the grace period between Product Owner and Distributor.

Supported tender communications with the Hospital Authority in Hong Kong as the Marketing Authorization Holder.

Provided comprehensive life cycle management services, including variations, pharmacovigilance services such as PSUR submission, ICSR, product defect handling, etc.

Delivered regulatory intelligence reports and dossier gap analysis to facilitate successful market entry.

A Hong Kong Marketing Authorization Holder must be a Companies Registry entity with a health-related scope and a permanent local address. We operate in that frame—holding authorization from the product owner when needed, filing through PRS 2.0, and keeping DH correspondence on the MAH desk where it belongs.

Classification matters here too: new chemical or biological entities, advanced therapy products, and biosimilars each demand a different evidence story before the Product Registration Number arrives.

Our team documents assumptions, authority expectations, and decision points so sponsors can approve the plan with clear risk ownership.

Local pharmacists and regulatory specialists stay accountable through query cycles, inspection readiness, and post-approval obligations.

We align labeling, Module 1 localization, and partner communications so commercial launch can follow approval without rework.

Where pathways differ by product class, we sequence filings to protect the critical path and avoid avoidable deficiency letters.

Engagements can scale from a single dossier workstream to a multi-country virtual regulatory function.

PECAN.Solutions scopes each workstream with milestones, document owners, and authority touchpoints so registration, license holding, and commercial access stay on one plan.